Reig Jofre

What Reig Jofre does

Reig Jofre (Laboratorio Reig Jofre, S.A.) is a Barcelona-headquartered, publicly listed Spanish pharmaceutical company founded in 1929. It develops, manufactures, markets, and distributes essential healthcare solutions spanning prescription specialty pharmaceuticals — antibiotics, hospital injectables, biosimilars, dermatology, women's health, and pediatrics — and consumer health brands including Forté Pharma (nutraceuticals), Sterimar (nasal hygiene), VINCOBIOSIS®, Regenail®, and Triferty-ATM®. The company operates a vertically integrated model combining R&D, sterile injectable manufacturing at its Toledo antibiotics plant, biopharmaceutical capabilities through the Syna Therapeutics joint venture with LeanBio (formed 2018, fully acquired December 2025), and a multi-country European commercial footprint via wholly-owned subsidiaries in Sweden (Bioglan), Poland, the Czech Republic, the United Kingdom, France, Portugal, and Italy.

The core technology platform rests on specialized pharmaceutical manufacturing — sterile injectables, beta-lactam antibiotics, and biosimilars — augmented by biotechnology capabilities via Syna Therapeutics and participation in EU-designated vaccine production capacity alongside Zendal. Reig Jofre's go-to-market is hybrid: enterprise field sales to hospitals, prescribers, and public health systems for its prescription portfolio; pharmacy, parapharmacy, and wholesale distribution for consumer health brands; and CDMO/licensing partnerships with companies such as Stada (Parkinson's manufacturing capacity at Bioglan) and LEO Pharma (psoriasis primary-care access from March 2025). The company maintains an own e-commerce channel for Forté Pharma (including in China) and a branded pharmacy-banner channel ("Reig Jofre Farmacias") in Spain.

Revenue is generated primarily through unit-priced sales of pharmaceutical SKUs at B2B distribution and pharmacy retail, supplemented by CDMO/licensing royalties and consumer brand sales. Reig Jofre was admitted to Spain's IBEX Small Cap index in June 2024 and is governed under Spanish public-company disclosure rules with CNMV filings, a scrip dividend program, and a liquidity contract with Solventis. Operational scale benchmarks include 15 million vials of intravenous anesthetic supplied to Japan, 2023 results of 17% revenue growth and 15% EBITDA growth, and a €13 million CDTI Innovación grant awarded in May 2025 under the EU IPCEI Med4Cure project for advanced therapy manufacturing infrastructure. The company employs between 1,001 and 5,000 people.

Name

Reig Jofre

Legal name

LABORATORIO REIG JOFRÉ, S.A.

Website

https://reigjofre.com

Company type

Public

Founded year

1929

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Reig Jofre is a Barcelona-based, publicly listed Spanish pharmaceutical company that develops, manufactures, and distributes specialty prescription medicines (antibiotics, biosimilars, hospital injectables, dermatology) and consumer health brands (Forté Pharma, Sterimar) across more than seven European markets and selected export geographies including Japan and China.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Specialty pharmaceuticals
• Hospital injectables
• Biosimilars manufacturing
• Antibiotic production
• Consumer health brands

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Specialty pharmaceutical product sales: Core revenue from sale of prescription specialty pharmaceuticals — antibiotics, hospital injectables, biosimilars, dermatology, women's health, and pediatrics — distributed through pharmacy networks, hospitals, and public health systems across Europe and selected international markets (e.g., anesthetic vials to Japan).
2. Consumer health & nutraceuticals (Forté Pharma and own-brand supplements): Revenue from sale of consumer health, dietary supplement and preventive-care brands (Forté Pharma, Sterimar and related lines) through pharmacy, parapharmacy, and own e-commerce storefronts targeting end consumers.
3. CDMO / industrial manufacturing and licensing services: Revenue from contract manufacturing, industrial development, and licensing services — including the Bioglan (Sweden) Parkinson's treatment capacity built for Stada (2021) and inclusion in EU-designated vaccine manufacturing capacity with Zendal (2023).
4. Biosimilar R&D and co-development (Syna Therapeutics): Revenue and equity participation from the 2018 Syna Therapeutics joint venture with LeanBio for biosimilar development, manufacturing and commercialization, plus R&D services rendered through academic and EU-funded programs (University of Santiago de Compostela, Med4Cure/IPCEI).

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels6 records

Core offering

Reig Jofre develops, produces, markets, and distributes essential healthcare solutions across prescription specialty pharmaceuticals (antibiotics, sterile injectables, biosimilars, hospital anti-infectives, dermatology, women's health, and pediatrics) and consumer health/nutraceutical brands (Forté Pharma, Sterimar, VINCOBIOSIS, Regenail, Triferty-ATM). The company also offers CDMO and licensing services through subsidiaries such as Bioglan (Sweden) and the Syna Therapeutics biosimilars joint venture, with EU-designated vaccine production capacity alongside Zendal.

Product overview

Reig Jofre operates a brand-and-subsidiary portfolio architecture rather than a single unified software product. The core platform is the Laboratorio Reig Jofre pharmaceutical manufacturing and distribution business, which develops, produces, markets and distributes essential healthcare solutions. This core is flanked by acquired sub-brands and consumer-health brands (Forté Pharma food supplements, Sterimar nasal hygiene, VINCOBIOSIS® dermatology, Reig Jofre Farmacias pharmacy channel, Regenail® and TRIFERTY-ATM® specialty products, and the Bioglan / Reig Jofre Sweden dermatology-and-Parkinson subsidiary). Advanced and biosimilar capabilities are operated through the Syna Therapeutics joint venture with LeanBio (biosimilars, including the LB-0702 license), and through the EMINTECH advanced-therapies initiative funded under the EU IPCEI Med4Cure program. The Reig Jofre Online Store (Tienda Online) serves as a consumer/employee channel for the portfolio. The product_overview reflects a multi-brand, multi-subsidiary pharmaceutical company; the named products above represent the actual portfolio captured.

Differentiator

Problem solved

Functional benefit

Brands

• FORTÉ PHARMA Laboratoires: Brand of dietary supplements / nutritional complements operated by Reig Jofre group, with e-commerce presence including in China.
• STERIMAR
• REIG JOFRE Farmacias
• Vincobiosis (VINCOBIOSIS®)
• Bioglan

Products and services

• Reig Jofre Pharmaceutical Portfolio (essential healthcare solutions) Core offering: development, manufacturing, marketing and distribution of essential healthcare solutions ranging from critical, specialized treatments to preventive care across all stages of patients' lives. Includes prescription pharmaceuticals, sterile injectables, antibiotics and hospital specialty products for healthcare professionals and patients.
• Forté Pharma Reig Jofre's food supplements and nutricosmetics brand (Forté Pharma Laboratoires), marketed internationally including via e-commerce in China, for end consumers seeking dietary supplements and preventive care products.
• Sterimar

Quantifiable outcome

• 17% revenue growth and 15% EBITDA growth in 2023
• +3 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered flagship, core and minor.

• LEO PharmaflagshipStrategic or Co-development Partner · 1 March 2025Partnership announced in March 2025 to improve access to psoriasis treatment in primary care. Combines Reig Jofre's specialty pharma and biosimilar capabilities with LEO Pharma's dermatology franchise to broaden patient access to psoriasis therapies outside of specialist hospital settings.
• LeanBiocoreStrategic or Co-development Partner · 1 January 2024Long-standing biotech partner of Reig Jofre. Co-founded the Syna Therapeutics biosimilars joint venture in 2018 and received a €5.8M capital injection from Reig Jofre in 2024 to reinforce biosimilar development and biotech integration.
• ZendalcoreStrategic or Co-development Partner · 1 January 2023Reig Jofre was designated alongside Zendal by the European Union in 2023 to provide vaccine production capacity, supporting EU pandemic preparedness and reinforcing Reig Jofre's vaccine manufacturing footprint.
• StadacoreStrategic or Co-development Partner · 1 January 2021Partnership established in 2021 through Bioglan (Reig Jofre's Swedish subsidiary) to add manufacturing capacity for a Parkinson's disease treatment, strengthening Reig Jofre's CDMO offering for neurology and central nervous system therapies.
• VaxdynminorStrategic or Co-development Partner · 1 January 2020Participation in the Vaxdyn vaccine biologicals development consortium from 2020, contributing to Reig Jofre's positioning in vaccine R&D and subsequent EU designation for vaccine production capacity.
• Syna TherapeuticsflagshipStrategic or Co-development Partner · 1 January 2018Joint venture established in 2018 between Reig Jofre and LeanBio to develop, manufacture and commercialize biosimilars. Syna Therapeutics is Reig Jofre's primary vehicle for proprietary biotech and biosimilar pipeline assets.
• University of Santiago de CompostelaminorStrategic or Co-development PartnerAcademic collaboration for the development of the Dexulac product, leveraging the university's research capabilities in joint R&D with Reig Jofre's pharmaceutical innovation teams.
• Med4Cure / IPCEI HealthcoreStrategic or Co-development PartnerEuropean consortium project (Important Project of Common European Interest in the Health sector) in which Reig Jofre participates to build advanced therapy manufacturing infrastructure, supported by a €13 million CDTI Innovación grant awarded in 2025.
• FarmaindustriaminorOthersMembership in Farmaindustria, the Spanish pharmaceutical industry association, supporting sector advocacy, policy engagement, and industry visibility for Reig Jofre in Spain.
• AESEG

Scale indicators6 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Faes Farma: Spanish specialty pharmaceutical company with OTC, prescription pharma and consumer health/nutraceutical brands. Directly comparable business mix to Reig Jofre's specialty pharma + Forté Pharma supplement portfolio.
• Zendal: Spanish biotechnology group focused on veterinary and human vaccines, designated alongside Reig Jofre by the EU in 2023 for vaccine production capacity. Closely comparable in pandemic-preparedness positioning and vaccine manufacturing scope.
• Almirall: Spanish specialty pharmaceutical company focused on dermatology and specialty products, listed in Barcelona. Closely comparable to Reig Jofre as a mid-cap Iberian pharma with dermatology franchises, hospital presence and pan-European commercialization.
• Laboratorios Rovi: Spanish specialty pharmaceutical company with proprietary manufacturing, biosimilars and CDMO services (Rovi Contract Manufacturing). Comparable as a mid-cap Iberian pharma with sterile injectable capacity and biosimilar strategy.
• Kern Pharma: Spanish generics and biosimilars subsidiary of Aurobindo. Comparable Spanish pharma with hospital tender exposure, biosimilar pipeline and pan-European distribution through parent group.
• Zambon: Italian privately-held specialty pharmaceutical company with branded prescription pharma and a CDMO business (Zambon Pharma). Comparable European mid-cap specialty pharma with similar international footprint.

Regional players

• Polpharma: Polish pharmaceutical manufacturer and one of the largest generics producers in Central Europe. Comparable as a regional European specialty/generics player relevant to Reig Jofre's Polish and Czech subsidiary markets.

Broad incumbents

• Hikma Pharmaceuticals: Listed mid-cap specialty pharma with generics, injectables and biosimilars across Europe, MENA and the US. Comparable business model mix and scale ambition to Reig Jofre's specialty + biosimilar + CDMO strategy.
• Stada Arzneimittel: Large European generics and specialty pharma group. Already a commercial partner of Reig Jofre via the Bioglan Parkinson's capacity deal (2021) and a benchmark for the type of scaled European specialty pharma Reig Jofre is moving toward.
• LEO Pharma: Global dermatology-focused pharmaceutical company headquartered in Denmark. Partner of Reig Jofre since March 2025 for psoriasis treatment access in primary care, providing a comparable dermatology specialty-pharma business model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xtwitter.com/ReigJofre
• YouTubeyoutube.com/channel/UCHekPA1NvsH0mSUjLeQx6UQ
• LinkedInlinkedin.com/company/laboratorio-reig-jofre
• Instagraminstagram.com/reigjofre

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Reig Jofre